Phenylpropiophenone derivatives as potential anticancer agents: Synthesis, biological evaluation and quantitative structure-activity relationship study

European Journal of Medicinal Chemistry

Volumn 63, Issue , 2013, Pages 239-255

  Ivković, Branka M ^a   Nikolic, Katarina ^a   Ilić, Bojana B ^a   Žižak, Željko S ^b   Novaković, Radmila B ^a   Čudina, Olivera A ^a   Vladimirov, Sote M ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Anticancer agents; Chalcones; Propafenone derivatives; QSAR

Indexed keywords

ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; PHENYLPROPIOPHENONE DERIVATIVE; PROPAFENONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN K 562; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HELA CELL; HUMAN; HUMAN CELL; PARTIAL LEAST SQUARES REGRESSION; PHARMACOPHORE; PREDICTIVE VALUE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHALCONE; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; MCF-7 CELLS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROPAFENONE; PROPIOPHENONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874936148     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.02.013     Document Type: Article

References (49)

1. P.B. Bach, J.R. Jett, U. Pastorino, M.S. Tockman, S.J. Swensen, and C.B. Begg Computed tomography screening and lung cancer outcomes JAMA 297 2007 953 962
2. H. Zhuang, J. Weiwei, C. Wei, Q. Kui, D. Wei, C. Lin, H. Qilai, Li Shufeng, D. Fei, C. Jen-Fu, F. Xue-Xun, Min Lu, and H. Zi-Chun Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis Lung Cancer 68 2010 27 38
3. C. Dyrager, M. Wickstroem, M. Friden-Saxin, A. Friberg, K. Dahlen, E.A.A. Wallen, J. Gullbo, M. Grotli, and K. Luthman Inhibitors and promoters of tubulin polymerization: synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents Bioorg. Med. Chem. 19 2011 2659 2665
4. D.I. Batovska, and T.I. Todorova Trends in utilization of the pharmacological potential of chalcones Curr. Clin. Pharmacol. 5 2010 1 29
5. I.K. Pajeva, and M. Wiese A comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance Quant. Struct. Act. Relat. 17 1998 301 312
6. G. Ecker, P. Chiba, M. Hitzler, D. Schmid, K. Visser, H.P. Cordes, J. Csöllei, J.K. Seydel, and K.J. Schaper Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance J. Med. Chem. 39 1996 4767 4774
7. B.F. Ruan, X. Lu, J.F. Tang, Y. Wei, X.L. Wang, Y.B. Zhang, L.S. Wang, and H.L. Zhu Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents Bioorg. Med. Chem. 19 2011 2688 2695
8. 1H)-ones, a new class of calcium entry blockers Bioorg. Med. Chem. Lett. 10 2000 1883 1885
9. F. Chimenti, R. Fioravanti, A. Bolasco, P. Chimenti, D. Secci, F. Rossi, M. Yáñez, F. Orallo, F. Ortuso, S. Alcaro, R. Cirilli, R. Ferretti, and M.L. Sanna A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors Bioorg. Med. Chem. 18 2010 1273 1279
10. F. Albrecht, J. Mueller, H. Lietz, W.W. Wiersdorff, H.G. Hege, C.D. Mueller, J. Gries, D. Lenke, G. Von Philipsborn, and M. Raschack Aminopropanol Derivatives of 2-hydroxy-phenylpropiophenones, Pharmaceutical Compositions and Use U.S. 1985 10 pp. Cont. of U.S. Ser. No. 416,228, abandoned. CODEN: USXXAM US 4540697 A 19850910 CAN 104:109222 AN 1986:109222
11. A.T. Dinkova-Kostova, M.A. Massiah, R.E. Bozak, R.J. Hicks, and P. Talalay Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups Proc. Natl. Acad. Sci. U S A 98 2001 3404 3409
12. B.M. Anderson, C.D. Anderson, G. Donzelli, and A. Dal Pozzo Sulfhydryl enzyme inactivation by nicotinoylacrylates Biochem. Biophys. Acta 703 1984 215 220
13. H.N. Pati, U. Das, I.J. Ramirez-Erosa, D.M. Dunlop, R.A. Hickie, and J.R. Dimmock α-substituted 1-aryl-3-dimethylaminopropanone hydrochlorides: potent cytotoxins towards human WiDr colon cancer cells Chem. Pharm. Bull. 55 2007 511 515
14. Y. Xia, Z.Y. Yang, P. Xia, K.F. Bastow, Y. Nakanishi, and K.H. Lee Antitumor agents. Part 202: novel 20-amino chalcones: design, synthesis and biological evaluation Bioorg. Med. Chem. Lett. 10 2000 699 701
15. Q. Li, and H.L. Sham Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer Expert Opin. Ther. Pat. 12 2002 1663 1702
16. H.M. Bryson, K.J. Palmer, H.D. Langtry, and A. Fitton Propafenone: a reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias Drugs 45 1993 85 130
17. D.J. Lowes, A.W. Guiguemde, M.C. Connelly, F. Zhu, M.S. Sigal, J.A. Clark, A.S. Lemoff, J.L. Derisi, E.B. Wilson, and K.R. Guy Optimization of propafenone analogues as antimalarial leads J. Med. Chem. 54 2011 7477 7485
18. P. Chiba, S. Burghofer, E. Richter, B. Tell, A. Moser, and G. Ecker Synthesis pharmacologic activity and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance J. Med. Chem. 38 1995 2789 2793
19. P. Chiba, B. Tell, W. Jäger, E. Richter, M. Hitzler, and G. Ecker Studies on propafenone-type modulators of multidrug-resistance IV: synthesis and pharmacological activity of 5-hydroxy and 5-benzyloxy derivatives Arch. Pharm. Pharm. Med. Chem. 330 1997 343 347
20. J.L. Fiske, V.P. Fomin, M.L. Brown, R.L. Ducan, and R.A. Sikes Voltage-sensitive ion channels in cancer Cancer Metastasis Rev. 25 2006 439 500
21. M. Li, and Z.G. Xiong Ion channels as targets for cancer therapy Int. J. Physiol. Pathophysiol. Pharmacol. 3 2011 156 166
22. J.Y. Le Guennec, H. Ouadid-Ahidouch, O. Soriani, P. Besson, A. Ahidouch, and C. Vandier Voltage-gated ion channels, new targets in anti-cancer research Recent Pat. Anticancer Drug Discov. 2 2007 189 202
23. L.A. Pardo Voltage-gated potassium channels in cell proliferation Physiology (Bethesda) 19 2004 285 292
24. A. Arcangeli, O. Crociani, E. Lastraioli, A. Masi, S. Pillozzi, and A. Becchetti Targeting ion channels in cancer: a novel frontier in antineoplastic therapy Curr. Med. Chem. 16 2009 66 93
25. A. Arcangeli, and A. Becchetti New trends in cancer therapy: targeting ion channels and transporters Pharmaceuticals 3 2010 1202 1224
26. K. Pleban, C. Hoffer, S. Kopp, M. Peer, and P. Chiba Intramolecular distribution of hydrophobicity influences pharmacologics of propafebu-type MDR modulators Arch. Pharm. Pharm. Med. Chem. 337 2004 328 334
27. C. Tmej, P. Chiba, M. Huber, E. Richter, M. Hitzler, K.-J. Schaper, and G. Ecker A combined Hansch/free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance Arch. Pharm. (Weinheim) 331 1998 233 240
28. L. Claisen, and A. Claparede Condensation of ketones with aldehydes Ber. Dtsch. Chem. Ges. 14 1981 2460 2480 From: J. Chem. Soc., Abstr. 1882, 42, 511-513
29. B. Ivković, S. Vladimirov, and R. Novaković The novel phenylpropiophenone derivates induced relaxation of isolated rat aorta Arzneimittelforschung 62 7 2012 345 350
30. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Meth. 65 1983 55 63
31. M. Ohno, and T. Abe Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) J. Immunol. Meth. 145 1991 199 203
32. W. Mahavorasirikul, V. Viyanant, W. Chaijaroenkul, A. Itharat, and K. Na-Bangchang Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro BMC Complement Altern. Med. 10 2010 55
33. ChemAxon Marvin 5.5.1.0 Program 2011 Budapest, Hungary www.chemaxon.com/products.html
34. J.J.P. Stewart Optimization of parameters for semi-empirical methods I-method J. Comput. Chem. 10 1989 209 220
35. J.J.P. Stewart Optimization of parameters for semiempirical methods. II. Applications J. Comput. Chem. 10 1989 221 264
36. 100 Cambridge Park Dr. Cambridge, MA 02140-2317, U.S.A. CS Chem3D Ultra 7.0, Cambridge Soft Corporation, (Property Picker ActiveX Control) 2001 http://www.cambridgesoft.com/
37. Dragon 6, TALETE srl, Via V. Pisani, 13-20124 Milano, Italy. http://www.talete.mi.it.
38. M.J. Frisch Gaussian 98 (Revision A.7) 1998 Gaussian, Inc. Pittsburgh PA
39. A.D. Becke Density-functional thermochemistry. III. The role of exact exchange J. Chem. Phys. 98 1993 5648 5652
40. C. Lee, W. Yang, and R.G. Parr Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density Phys. Rev. B Condens. Matter 37 1988 785 789
41. C.C.J. Roothaan New developments in molecular orbital theory Rev. Mod. Phys. 23 1951 69 89
42. L. Eriksson, E. Johansson, N. Kettaneh-Wold, J. Trygg, C. Wikstrom, and S. Wold Multi- and Megavariate Data Analysis. Basic Principles and Applications I second ed. 2001 Umetrics Academy Umeå
43. A.B. Umetrics SIMCA P+ Program, Version 12.0.0.0 Umea, Sweden May 20, 2008 www.umetrics.com
44. A. Tropsha Best practices for QSAR model development, validation, and exploitation Mol. Inf. 29 2010 476 488
45. D.M. Allen The relationship between variable selection and data augmentation and a method for prediction Technometrics 16 1974 125 127
46. L. Ståhle, and S. Wold Analysis of variance (ANOVA) Chemometr. Intell. Lab. Syst. 6 1989 259 272
47. S. Wold, E. Johansson, and M. Cocchi 3D QSAR in drug design, theory, methods, and applications H. Kubinyi, 1993 ESCOM Science Publishers Leiden 523 550
48. Pentacle, Version 1.0.6 2009 Molecular Discovery Ltd. Perugia, Italy
49. M. Pastor, G. Cruciani, I. McLay, S. Pickett, and S. Clementi J. Med. Chem. 43 2000 3233 3243